Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)

被引：40
|
作者：
Bethel, M. Angelyn
Mentz, Robert J.
Merrill, Peter
Buse, John B.
Chan, Juliana C.
Goodman, Shaun G.
Iqbal, Nayyar
Jakuboniene, Neli
Katona, Brian G.
Lokhnygina, Yuliya
Lopes, Renato D.
Maggioni, Aldo P.
Ohman, Peter K.
Poulter, Neil R.
Ramachandran, Ambady
Tankova, Tsvetalina
Zinman, Bernard
Hernandez, Adrian F.
Holman, Rury R.
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-522-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial
    Neves, Joao Sergio
    Leite, Ana Rita
    Mentz, Robert J.
    Holman, Rury R.
    Zannad, Faiez
    Butler, Javed
    Packer, Milton
    Ferreira, Joao Pedro
    EUROPEAN JOURNAL OF HEART FAILURE, 2024,
  • [12] Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
    Reed, Shelby D.
    Li, Yanhong
    Dakin, Helen A.
    Becker, Frauke
    Leal, Jose
    Gustavson, Stephanie M.
    Kartman, Bernt
    Wittbrodt, Eric
    Mentz, Robert J.
    Pagidipati, Neha J.
    Bethel, M. Angelyn
    Gray, Alastair M.
    Holman, Rury R.
    Hernandez, Adrian F.
    DIABETES CARE, 2020, 43 (02) : 374 - 381
  • [13] Effect of Open-Label SGLT2 Inhibitor Treatment When Combined with Exenatide on Cardiovascular and Renal Outcomes in EXSCEL
    Clegg, Lindsay E.
    Penland, Robert C.
    Boulton, David W.
    Bachina, Srinivas
    Thuresson, Marcus
    Heerspink, Hiddo L.
    Gustavson, Stephanie
    Sjostrom, C. David
    Ruggles, James A.
    Hernandez, Adrian F.
    Buse, John B.
    Mentz, Robert J.
    Holman, Rury R.
    DIABETES, 2019, 68
  • [14] Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
    Bethel, M. Angelyn
    Mentz, Robert J.
    Merrill, Peter
    Buse, John B.
    Chan, Juliana C.
    Goodman, Shaun G.
    Iqbal, Nayyar
    Jakuboniene, Neli
    Katona, Brian
    Lokhnygina, Yuliya
    Lopes, Renato D.
    Maggioni, Aldo P.
    Ohman, Peter
    Tankova, Tsvetalina
    Bakris, George L.
    Hernandez, Adrian F.
    Holman, Rury R.
    DIABETES CARE, 2020, 43 (02) : 446 - 452
  • [15] Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease: Prespecified Analysis From EXSCEL
    Mentz, Robert J.
    Thompson, Vivian P.
    Aguilar, David
    Choi, Jasmine
    Gustavson, Stephanie M.
    Iqbal, Nayyar
    Kong, Alice P.
    Ohman, Peter
    Sattar, Naveed
    Scott, Russell S.
    Wong, Yee Weng
    Holman, Rury R.
    Hernandez, Adrian F.
    CIRCULATION, 2018, 138 (22) : 2576 - 2578
  • [16] Exenatide and cardiovascular outcomes
    Kang, Seema
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (11): : 850 - 850
  • [17] Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights From the EXSCEL Trial
    Mentz, Robert J.
    Bethel, M. Angelyn
    Thompson, Vivian P.
    Lokhnygina, Yuliya
    Buse, John B.
    Chan, Julian C.
    Choi, Jasmine
    Gustavson, Stephanie M.
    Iqbal, Nayyar
    Maggioni, Aldo P.
    Marso, Steven P.
    Ohman, Peter
    Pagidipati, Neha J.
    Poulter, Neil
    Ramachandran, Ambady
    Zinman, Bernard
    Holman, Rury R.
    Hernandez, Adrian F.
    CIRCULATION, 2017, 136 (24) : E455 - E455
  • [18] Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL
    Idzerda, Nienke M. A.
    Clegg, Lindsay E.
    Hernandez, Adrian F.
    Bakris, George
    Penland, Robert C.
    Boulton, David W.
    Bethel, M. Angelyn
    Holman, Rury R.
    Heerspink, Hiddo J. L.
    DIABETES OBESITY & METABOLISM, 2020, 22 (05): : 798 - 806
  • [19] Effects of once-weekly exenatide on clinical outcomes in the subgroup of patients with pre-existing cardiovascular disease: insights from EXSCEL
    Mentz, R. J.
    Thompson, V. P.
    Gustavson, S. M.
    Iqbal, N.
    Ohman, P.
    Holman, R. R.
    Hernandez, A. F.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1082 - 1082
  • [20] Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
    Lindsay E. Clegg
    Robert C. Penland
    Srinivas Bachina
    David W. Boulton
    Marcus Thuresson
    Hiddo J. L. Heerspink
    Stephanie Gustavson
    C. David Sjöström
    James A. Ruggles
    Adrian F. Hernandez
    John B. Buse
    Robert J. Mentz
    Rury R. Holman
    Cardiovascular Diabetology, 18
12345